Top Markets
#1 Bitway Bitway +54.75%
#2 Starpower Starpower +38.81%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +38.71%
#4 Pons Pons +35.55%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.98%
#6 aelf aelf +22.42%
#7 OpenEden OpenEden +19.79%
#8 SkyAI SkyAI +19.70%
#9 Ocean Protocol Ocean Protocol +18.30%
#10 Decred Decred +14.81%
Coin of the day
Bitway Bitway
Settings
Language
ENGLISH
Currency
USD
Theme
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Rank in Stocks #29652
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Share Price
$0.68377137
Last synced: 2023-05-23
Market Cap
$20.23M
Change (1 day)
-0.60%
Change (1 year)
0.00%
Country
SE
Trade Medivir AB (publ) (MVIR-B)

Category

Healthcare
Revenue for Medivir AB (publ) (MVIR-B)
Revenue in Aug 2026 TTM: 0
According to Medivir AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Medivir AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH